Clinical Trials Directory

Trials / Unknown

UnknownNCT02044185

Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation

Observational Study for Clinical Implications of HMGB1 (High-mobility Group Protein B1) in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Seoul St. Mary's Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell transplantation is one of the meaningful issues in aspect of patient's recovery and survival. in recent years, the understanding of the pathology of GVHD is much important to prevent or treat aGVHD. additionally, (oral) mucositis is one of the problems in patients with high dose chemotherapy, and mucositis by high-dose chemotherapy is related to HMGB-1 as proinflamtory cytokines. HMGB1 is a nuclear protein acts as a transcription factor, but, if it was released to the outside of cells by damaged cell or necrotic tissues, it works as cytokines for promoter of inflammation and cancers. at this point, there are no reported articles about correlation of HMGB1 and aGVHD in human. recently, we have seen excessive secretion of serum HMGB1 in mouse model, then base on this results, we will check correlation of HMGB1 and aGVHD/ oral mucositis in human.

Detailed description

1. materials 1) inclusion criteria 1. over 18-year-old 2. patients with myeloablative conditioning regimen 3. autologous transplant 4. patients with confirmation of acute GVHD as over grade II 5. patients with salvage chemotherapy 2\) exclusion criteria <!-- --> 1. old age ( over 60-year-old) 2. patients with reduced intensity stem cell transplantation 2. method 1) check the serum level of HMGB1, TNF-a, IL-1b, IL-6, Th1, Th2, Th17, FoxP3 on 7-day before transplant day(D-7), transplant day(D0), 7-day after transplant(D+7), D+14, D+21. 2) check the immunohistochemistry level of tissue in diagnosed aGVHD ( performed sigmoidoscopy and random biopsy of gut is routine process in our center) 3) check the oral mucositis grades (using WHO grading system, NCI -CTC ver.3 scoring system) 3. analysis 1) student t-test , chi-square test 2) survival analysis

Conditions

Interventions

TypeNameDescription
DRUGsalvage chemotherapy, total body irradiationthere are no direct interventions to our patients.

Timeline

Start date
2014-01-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2014-01-23
Last updated
2015-04-22

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02044185. Inclusion in this directory is not an endorsement.